New classes of glaucoma medications

Emily M. Schehlein, Gary D. Novack, Alan L. Robin

Research output: Contribution to journalReview articlepeer-review


Purpose of review To discuss recent advances in the medical management of glaucoma and to highlight future medical therapies currently in development. Recent findings In 1996, latanoprost (Xalatan) was approved in the United States as a new chemical entity and new class (prostaglandin analogs) for the topical treatment of ocular hypertension and glaucoma. In the period from the late 1990s-2010s, while there were additional new chemical entities, fixed dose combinations, and formulation improvements, there were no new classes of ocular hypotensive medications approved worldwide. We summarize new pharmacological treatments that are currently in clinical trials-new classes, new molecules and new delivery systems. Summary Although challenges in medical treatment of glaucoma exist, particularly in patient adherence, medical therapy remains the first line treatment for almost all glaucoma patients. Few new medications for glaucoma therapy are currently available for our patients, but multiple drugs with novel mechanisms of action, new formulations, and new delivery mechanisms are currently in development.

Original languageEnglish (US)
Pages (from-to)161-168
Number of pages8
JournalCurrent Opinion in Ophthalmology
Issue number2
StatePublished - Mar 1 2017


  • drug delivery
  • glaucoma
  • medications

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'New classes of glaucoma medications'. Together they form a unique fingerprint.

Cite this